Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 923 shares at $8.86 ($7K) on 2012-01-11, disclosed to the SEC on 2012-01-12.
Scheduled purchase ($7k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.50 | 76 | $494 | 7.1% |
| 2 | $6.52 | 455 | $3K | 42.8% |
| 3 | $6.53 | 1 | $7 | 0.1% |
| 4 | $8.86 | 191 | $2K | 24.4% |
| 5 | $8.87 | 200 | $2K | 25.6% |
| Total | $7.51 avg | 923 |
| $7K |
| 100% |
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |